| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA synthesis. [Wikipedia] |
| Indication |
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) |
| Pharmacology |
Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. |
| Toxicity |
Kidney damage, fall in the number of white blood cells, decreased platelets |
| Affected Organisms |
| • |
Human Immunodeficiency Virus |
|
| Absorption |
100% |
| Half Life |
2.4 to 3.2 hours |
| Protein Binding |
6% |
| Distribution |
* 537 ± 126 mL/kg [VISTIDE ADMINISTERED WITHOUT PROBENECID]
* 410 ± 102 mL/kg [VISTIDE ADMINISTERED WITH PROBENECID] |
| Clearance |
* 179 +/- 23.1 mL/min/1.73 m2 [WITHOUT PROBENECID]
* 148 +/- 38.8 mL/min/1.73 m2 [WITH PROBENECID] |
| External Links |
|